General form of registration statement for all companies including face-amount certificate companies

Note 8 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities 3 (Details)

v3.24.4
Note 8 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities 3 (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Royalty agreement liabilities $ 1,587 $ 9,080
Net operating loss carryforwards 9,179 7,850
Capitalized R&D 4,548 3,152
Accrued expenses, tax assets 406 364
Orphan drug credit 199 199
Startup costs 95 104
Total deferred tax assets 16,014 20,749
Less: valuation allowance: (16,014) (20,749)
Net deferred tax asset 0 0
Decrease (increase) in valuation allowance $ 4,735 $ (4,637)